Open Access Articles- Top Results for 5-APDI


Systematic (IUPAC) name
Clinical data
13396-94-6 7pxN
PubChem CID 192600
ChemSpider 167142 7pxY
Synonyms 1-(5-indanyl)-2-aminopropane
Chemical data
Formula C12H17N
175.27 g/mol
 14pxY (what is this?)  (verify)

5-(2-Aminopropyl)-2,3-dihydro-1H-indene (5-APDI), also known as indanylaminopropane (IAP), IAP (psychedelic), 2-API(2-aminopropylindane), indanametamine, and, incorrectly, as indanylamphetamine,[1] is an entactogen and psychedelic drug of the amphetamine family.[2][3] It has been sold by online vendors through the Internet and has been encountered as a designer drug since 2003,[1] but its popularity and availability has diminished in recent years.

5-APDI acts as a potent and weakly selective serotonin releasing agent (SSRA) with IC50 values of 82 nM, 1,848 nM, and 849 nM for inhibiting the reuptake of serotonin, dopamine, and norepinephrine, respectively.[2][3] It fully substitutes for MBDB but not amphetamine in trained animals, though it does produce disruption for the latter at high doses.[2] [4] 5-ADPI has been classified as a class B drug under the Misuse of Drugs Act 1971 since 10th June 2014

See also


  1. ^ a b Casale JF, McKibben TD, Bozenko JS, Hays PA (2005). "Characterization of the "Indanylamphetamines"". Microgram Journal 3 (1–2): 3–10. 
  2. ^ a b c Monte AP, Marona-Lewicka D, Cozzi NV, Nichols DE (November 1993). "Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4-(methylenedioxy)amphetamine". Journal of Medicinal Chemistry 36 (23): 3700–6. PMID 8246240. doi:10.1021/jm00075a027. 
  3. ^ a b Parker MA, Marona-Lewicka D, Kurrasch D, Shulgin AT, Nichols DE (March 1998). "Synthesis and pharmacological evaluation of ring-methylated derivatives of 3,4-(methylenedioxy)amphetamine (MDA)". Journal of Medicinal Chemistry 41 (6): 1001–5. PMID 9526575. doi:10.1021/jm9705925. 
  4. ^


External links

Cite error: <ref> tags exist, but no <references/> tag was found